{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:59:49Z","timestamp":1792929589357,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Dengtang Liu","award":["CRC2017ZD03, 82171496, 82371504, 20y11906300, 2022JC009, GWVI-11.2-YQ39, 22Y11903400, 23ZR1454700, YG2017ZD13, 19MC1911100, 13dz2260500, YG2024QNA55, 2024ZZ2058, 2024-YJ06."],"award-info":[{"award-number":["CRC2017ZD03, 82171496, 82371504, 20y11906300, 2022JC009, GWVI-11.2-YQ39, 22Y11903400, 23ZR1454700, YG2017ZD13, 19MC1911100, 13dz2260500, YG2024QNA55, 2024ZZ2058, 2024-YJ06."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-06802-7","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:54:09Z","timestamp":1746683649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identifying serum lipidomic signatures related to prognosis in first-episode schizophrenia"],"prefix":"10.1186","volume":"25","author":[{"given":"Mengyi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuke","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiming","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengtang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"6802_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/89040","volume":"7","author":"GK Thaker","year":"2001","unstructured":"Thaker GK, Carpenter WT. Advances in schizophrenia. Nat Med. 2001;7:667\u201371.","journal-title":"Nat Med"},{"key":"6802_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2010.05.025","volume":"122","author":"R Tandon","year":"2010","unstructured":"Tandon R, Nasrallah HA, Keshavan MS, Schizophrenia. Just the facts 5. Treatment and prevention past, present, and future. Schizophr Res. 2010;122:1\u201323.","journal-title":"Schizophr Res"},{"issue":"Suppl 1","key":"6802_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4088\/JCP.10075su1.01","volume":"72","author":"R Tandon","year":"2011","unstructured":"Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry. 2011;72(Suppl 1):4\u20138.","journal-title":"J Clin Psychiatry"},{"key":"6802_CR4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","volume":"72","author":"O Agid","year":"2011","unstructured":"Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72:1439\u201344.","journal-title":"J Clin Psychiatry"},{"key":"6802_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3389\/fnins.2016.00488","volume":"10","author":"RI Castillo","year":"2016","unstructured":"Castillo RI, Rojo LE, Henriquez-Henriquez M, Silva H, Maturana A, Villar MJ, et al. From molecules to the clinic: linking schizophrenia and metabolic syndrome through sphingolipids metabolism. Front Neurosci. 2016;10:488.","journal-title":"Front Neurosci"},{"key":"6802_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2017.03.031","volume":"190","author":"B Misiak","year":"2017","unstructured":"Misiak B, Sta\u0144czykiewicz B, \u0141aczma\u0144ski \u0141, Frydecka D. Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis. Schizophr Res. 2017;190:18\u201327.","journal-title":"Schizophr Res"},{"key":"6802_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.schres.2015.07.013","volume":"168","author":"S Smesny","year":"2015","unstructured":"Smesny S, Gussew A, Biesel NJ, Schack S, Walther M, Rzanny R, et al. Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients. Schizophr Res. 2015;168:322\u20139.","journal-title":"Schizophr Res"},{"key":"6802_CR8","doi-asserted-by":"publisher","first-page":"e906","DOI":"10.1038\/tp.2016.142","volume":"6","author":"C Tessier","year":"2016","unstructured":"Tessier C, Sweers K, Frajerman A, Bergaoui H, Ferreri F, Delva C, et al. Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations. Transl Psychiatry. 2016;6:e906.","journal-title":"Transl Psychiatry"},{"key":"6802_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pscychresns.2011.06.017","volume":"201","author":"J Miller","year":"2012","unstructured":"Miller J, Drost DJ, Jensen E, Manchanda R, Northcott S, Neufeld RWJ, et al. Progressive membrane phospholipid changes in first episode schizophrenia with high field magnetic resonance spectroscopy. Psychiatry Res Neuroimaging. 2012;201:25\u201333.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"6802_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/jnr.21822","volume":"87","author":"S Narayan","year":"2009","unstructured":"Narayan S, Head SR, Gilmartin TJ, Dean B, Thomas EA. Evidence for disruption of sphingolipid metabolism in schizophrenia. J Neurosci Res. 2009;87:278.","journal-title":"J Neurosci Res"},{"key":"6802_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/sj.mp.4002000","volume":"12","author":"R Kaddurah-Daouk","year":"2007","unstructured":"Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007;12:934\u201345.","journal-title":"Mol Psychiatry"},{"key":"6802_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.mp.4001425","volume":"8","author":"EA Thomas","year":"2003","unstructured":"Thomas EA, George RC, Danielson PE, Nelson PA, Warren AJ, Lo D, et al. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol Psychiatry. 2003;8:983\u201393.","journal-title":"Mol Psychiatry"},{"key":"6802_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psychres.2010.07.049","volume":"186","author":"T Sumiyoshi","year":"2011","unstructured":"Sumiyoshi T, Higuchi Y, Matsui M, Itoh H, Uehara T, Itoh T, et al. Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia. Psychiatry Res. 2011;186:23\u20137.","journal-title":"Psychiatry Res"},{"key":"6802_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jpsychires.2015.11.013","volume":"73","author":"T Pawe\u0142czyk","year":"2016","unstructured":"Pawe\u0142czyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawe\u0142czyk A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res. 2016;73:34\u201344.","journal-title":"J Psychiatr Res"},{"key":"6802_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1600-0447.1988.tb06388.x","volume":"78","author":"O Christensen","year":"1988","unstructured":"Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand. 1988;78:587\u201391.","journal-title":"Acta Psychiatr Scand"},{"key":"6802_CR16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2174\/1570159X17666190228113348","volume":"17","author":"DD Kim","year":"2019","unstructured":"Kim DD, Barr AM, Fredrikson DH, Honer WG, Procyshyn RM. Association between serum lipids and antipsychotic response in schizophrenia. Curr Neuropharmacol. 2019;17:852.","journal-title":"Curr Neuropharmacol"},{"key":"6802_CR17","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.jlr.2021.100164","volume":"63","author":"X Han","year":"2021","unstructured":"Han X, Gross RW. The foundations and development of lipidomics. J Lipid Res. 2021;63:100164.","journal-title":"J Lipid Res"},{"key":"6802_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jssc.201700709","volume":"41","author":"T Hu","year":"2018","unstructured":"Hu T, Zhang J-L. Mass-spectrometry-based lipidomics. J Sep Sci. 2018;41:351\u201372.","journal-title":"J Sep Sci"},{"key":"6802_CR19","doi-asserted-by":"publisher","first-page":"109945","DOI":"10.1016\/j.pnpbp.2020.109945","volume":"101","author":"V De Almeida","year":"2020","unstructured":"De Almeida V, Alexandrino GL, Aquino A, Gomes AF, Murgu M, Dobrowolny H, et al. Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2020;101:109945.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6802_CR20","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jamapsychiatry.2022.4350","volume":"80","author":"A Tkachev","year":"2023","unstructured":"Tkachev A, Stekolshchikova E, Vanyushkina A, Zhang H, Morozova A, Zozulya S, et al. Lipid alteration signature in the blood plasma of individuals with schizophrenia, depression, and bipolar disorder. JAMA Psychiatry. 2023;80:250\u20139.","journal-title":"JAMA Psychiatry"},{"key":"6802_CR21","doi-asserted-by":"publisher","first-page":"115070","DOI":"10.1016\/j.psychres.2023.115070","volume":"321","author":"M Song","year":"2023","unstructured":"Song M, Liu Y, Zhou J, Shi H, Su X, Shao M, et al. Potential plasma biomarker panels identification for the diagnosis of first-episode schizophrenia and monitoring antipsychotic monotherapy with the use of metabolomics analyses. Psychiatry Res. 2023;321:115070.","journal-title":"Psychiatry Res"},{"key":"6802_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.schres.2020.11.010","volume":"230","author":"X Li","year":"2021","unstructured":"Li X, Guo X, Fan X, Feng T, Wang C, Yao Z, et al. Sequential Multiple-Assignment randomized trials to compare antipsychotic treatments (SMART-CAT) in first-episode schizophrenia patients: rationale and trial design. Schizophr Res. 2021;230:87\u201394.","journal-title":"Schizophr Res"},{"key":"6802_CR23","doi-asserted-by":"crossref","unstructured":"Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005;39:1\u201330.","DOI":"10.1111\/j.1440-1614.2005.01516.x"},{"key":"6802_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2005.06.004","volume":"78","author":"WW Fleischhacker","year":"2005","unstructured":"Fleischhacker WW, Keet IPM, Kahn RS. The European first episode schizophrenia trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005;78:147\u201356.","journal-title":"Schizophr Res"},{"key":"6802_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"6802_CR26","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry Edgmont. 2007;4:28.","journal-title":"Psychiatry Edgmont"},{"key":"6802_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","volume":"75","author":"S Leucht","year":"2014","unstructured":"Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry. 2014;75:8\u201314.","journal-title":"J Clin Psychiatry"},{"key":"6802_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","volume":"172","author":"MT Samara","year":"2015","unstructured":"Samara MT, Leucht C, Leeflang MM, Anghelescu I-G, Chung Y-C, Crespo-Facorro B, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: A diagnostic test review. Am J Psychiatry. 2015;172:617\u201329.","journal-title":"Am J Psychiatry"},{"key":"6802_CR29","unstructured":"Chen L, Huai C, Song C, Wu S, Xu Y, Yi Z, et al. Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction. Mol Psychiatry. 2024;1\u201310. https:\/\/www.nature.com\/articles\/s41380-024-02841-w"},{"key":"6802_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1\u201322.","journal-title":"J Stat Softw"},{"key":"6802_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn. 2001;45:5\u201332.","journal-title":"Mach Learn"},{"key":"6802_CR32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373\u20139.","journal-title":"J Clin Epidemiol"},{"key":"6802_CR33","doi-asserted-by":"publisher","first-page":"17679","DOI":"10.1038\/s41598-024-68706-y","volume":"14","author":"S Zheng","year":"2024","unstructured":"Zheng S, He H, Zheng J, Zhu X, Lin N, Wu Q, et al. Machine learning-based screening and validation of liver metastasis-specific genes in colorectal cancer. Sci Rep. 2024;14:17679.","journal-title":"Sci Rep"},{"key":"6802_CR34","doi-asserted-by":"publisher","first-page":"8544","DOI":"10.1007\/s12035-024-03948-5","volume":"61","author":"G Yang","year":"2024","unstructured":"Yang G, Zhang B, Xu CY, Wu JW, Zhang Y, Yu Y, et al. Utilizing machine learning to identify biomarkers of Endoplasmic reticulum stress and analyze immune cell infiltration in Parkinson\u2019s disease. Mol Neurobiol. 2024;61:8544\u201351.","journal-title":"Mol Neurobiol"},{"key":"6802_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1681\/ASN.2021040538","volume":"33","author":"AM Lee","year":"2022","unstructured":"Lee AM, Hu J, Xu Y, Abraham AG, Xiao R, Coresh J, et al. Using machine learning to identify metabolomic signatures of pediatric chronic kidney disease etiology. J Am Soc Nephrol JASN. 2022;33:375\u201386.","journal-title":"J Am Soc Nephrol JASN"},{"key":"6802_CR36","doi-asserted-by":"crossref","unstructured":"Sethi S, Hayashi MAF, Barbosa BS, Pontes JGM, Tasic L, Brietzke E. Lipidomics, Biomarkers, and Schizophrenia: a current perspective. Adv Exp Med Biol. 2017;965:265\u201390.","DOI":"10.1007\/978-3-319-47656-8_11"},{"key":"6802_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00406-018-0971-6","volume":"270","author":"L Leppik","year":"2020","unstructured":"Leppik L, Parksepp M, Janno S, Koido K, Haring L, Vasar E, et al. Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci. 2020;270:59\u201370.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"6802_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.pscychresns.2013.06.011","volume":"214","author":"W Weber-Fahr","year":"2013","unstructured":"Weber-Fahr W, Englisch S, Esser A, Tunc-Skarka N, Meyer-Lindenberg A, Ende G, et al. Altered phospholipid metabolism in schizophrenia: A phosphorus 31 nuclear magnetic resonance spectroscopy study. Psychiatry Res Neuroimaging. 2013;214:365\u201373.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"6802_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.psychres.2018.12.008","volume":"272","author":"D Wang","year":"2019","unstructured":"Wang D, Cheng SL, Fei Q, Gu H, Raftery D, Cao B, et al. Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia. Psychiatry Res. 2019;272:18\u201329.","journal-title":"Psychiatry Res"},{"key":"6802_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jpsychires.2017.08.009","volume":"95","author":"S Ghosh","year":"2017","unstructured":"Ghosh S, Dyer RA, Beasley CL. Evidence for altered cell membrane lipid composition in postmortem prefrontal white matter in bipolar disorder and schizophrenia. J Psychiatr Res. 2017;95:135\u201342.","journal-title":"J Psychiatr Res"},{"key":"6802_CR41","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/schbul\/sbac011","volume":"48","author":"M Li","year":"2022","unstructured":"Li M, Gao Y, Wang D, Hu X, Jiang J, Qing Y, et al. Impaired membrane lipid homeostasis in schizophrenia. Schizophr Bull. 2022;48:1125\u201335.","journal-title":"Schizophr Bull"},{"key":"6802_CR42","first-page":"264","volume":"5","author":"CS Haszto","year":"2020","unstructured":"Haszto CS, Stanley JA, Iyengar S, Prasad KM. Regionally distinct alterations in membrane phospholipid metabolism in schizophrenia: A Meta-analysis of phosphorus magnetic resonance spectroscopy studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5:264\u201380.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"6802_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.psychres.2012.02.019","volume":"198","author":"R Kaddurah-Daouk","year":"2012","unstructured":"Kaddurah-Daouk R, McEvoy J, Baillie R, Zhu H, Yao K, Nimgaonkar J. Impaired plasmalogens in patients with schizophrenia. Psychiatry Res. 2012;198:347\u201352.","journal-title":"Psychiatry Res"},{"key":"6802_CR44","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1021\/pr300459d","volume":"11","author":"H-L Cai","year":"2012","unstructured":"Cai H-L, Li H-D, Yan X-Z, Sun B, Zhang Q, Yan M, et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-na\u00efve schizophrenia patients after treatment with Risperidone. J Proteome Res. 2012;11:4338\u201350.","journal-title":"J Proteome Res"},{"key":"6802_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.psychres.2009.01.009","volume":"169","author":"P Nuss","year":"2009","unstructured":"Nuss P, Tessier C, Ferreri F, De Hert M, Peuskens J, Trugnan G, et al. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res. 2009;169:91\u20136.","journal-title":"Psychiatry Res"},{"key":"6802_CR46","doi-asserted-by":"publisher","first-page":"e1130","DOI":"10.1038\/tp.2017.94","volume":"7","author":"HL Cai","year":"2017","unstructured":"Cai HL, Jiang P, Tan QY, Dang RL, Tang MM, Xue Y, et al. Therapeutic efficacy of atypical antipsychotic drugs by targeting multiple stress-related metabolic pathways. Transl Psychiatry. 2017;7:e1130.","journal-title":"Transl Psychiatry"},{"key":"6802_CR47","first-page":"331","volume":"32","author":"RM Procyshyn","year":"2007","unstructured":"Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EYH, Pomarol-Clotet E, et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci JPN. 2007;32:331\u20138.","journal-title":"J Psychiatry Neurosci JPN"},{"key":"6802_CR48","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.eurpsy.2003.06.002","volume":"18","author":"G Garyfallos","year":"2003","unstructured":"Garyfallos G, Dimelis D, Kouniakis P, Sidiropoulos N, Karastergiou A, Lavrentiadis G, et al. Olanzapine versus Risperidone: weight gain and elevation of serum triglyceride levels. Eur Psychiatry J Assoc Eur Psychiatr. 2003;18:320\u20131.","journal-title":"Eur Psychiatry J Assoc Eur Psychiatr"},{"key":"6802_CR49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ajp.2014.05.001","volume":"11","author":"E Sharma","year":"2014","unstructured":"Sharma E, Venkatasubramanian G, Varambally S, Sivakumar PT, Subbakrishna DK, Gangadhar BN. Antipsychotic induced metabolic changes & treatment response: A prospective study. Asian J Psychiatry. 2014;11:39\u201344.","journal-title":"Asian J Psychiatry"},{"key":"6802_CR50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00004850-200207000-00007","volume":"17","author":"S Pande","year":"2002","unstructured":"Pande S, Procyshyn RM, Nazerali M, Attwood D, Chow K. Do triglycerides modulate the effectiveness of clozapine? Int Clin Psychopharmacol. 2002;17:197\u20139.","journal-title":"Int Clin Psychopharmacol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06802-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06802-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06802-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T07:02:46Z","timestamp":1746687766000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06802-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6802"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06802-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Shanghai Mental Health Center. All participants provided written informed consents. All procedures carried out in the study comply with the Declaration of Helsinki for experiments involving humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual data is presented, and consent to publication is therefore not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"467"}}